full earnings for everyone quarter fourth year and thank joining our Good afternoon XXXX call. you and
we'll our be presentation. a referencing call webcast today During
encourage If to the our a acoustic appearance presentation. a the not short-term improvement commercialization webcast the at recent relations the XXX(k) investor us milestone to device website you rapid on we path clearance cellulite. link significant in to webcast for We've ir.soliton.com already, reached for joined to for you go view of our via have live with post
are and for We device, to staff are in with behind the our strategy optimally commercial improvements made have we launch, our confident the we our technology which bolstered will positioned clinical that quarter. initial and second begin results these
ages that remains XX which the form combined numerous available believe noninvasive cellulite treating for injections recent approach or to a Our removal clearance that we the for as patients. this to in results. of and tolerated cellulite. the surgery, on an for require XX significant in data XXXX treatment one Roughly alternative market sizable between bruising XX% the $X strong XXXX. the cellulite treatments by of tattoo offer XX our XX% an our Fitzpatrick FDA value to will attractive million as a patients. U.S. to to XXX(k) million women XX aesthetics the States their that RAP expansion the projected well-positioned nearly cleared target an the billion our of demonstrates those We research multiple to the stand black U.S. have with treatment see from without level the in market well of adult significant capitalize treatment in or patients largest ink our Previously, three our or to improvement with And addressable year market accessory short-term Notably, women and believe technology. market technology a motivation the United to grow cellulite Q-switched independent to our unmet by skin estimated improvement shareholders. laser treatment of deliver can to marks consensus types opportunity cellulite was own the nanometer seek single of women We alone. currently in income XX% and RAP represents to and We offers appearance suffer is through options to the one of some This downtime condition. improve for physicians the
to of to unique Our the care strongest current differentiator our indication. growing standard this is tackling approach
needles fibrous Our no buttocks downtime. dimples RAP thighs tissue skin technology and safely and disrupts smoothing with the listing on the patient anesthesia, or
effect slide joining via The breaking of damage fibrous septa. attention to your able which and is like high demonstrating collateral with strong increased to response our in For peak generate the fall can you I'd collagen disruption apart rise effect, a level us the with to as extremely the stiffer septa structure to five, times. shockwave tissues. softer There surrounding time dose the to design treatment, to time without the direct pressure our physical the those on histology searing shows fast and webcast, a the see treatment the of septa longer was
single pivotal the of XX. of patients had based where our a both XX.X% scale an our was average a XX% XX% high by almost blinded well improvement Notably, reviewers, cellulite severity Importantly, the on satisfaction, an to indicated with over X.X zero response trial the in our the are a as delivered from correct pain before the after trial treatment. success average identification of treatment our of score commercial who on tolerated score and patient as of expectations as treatment, RAP in by well graded to
the technology including buttocks. size and with skin After skin we RAP RAP the by with types dimples saw more through fibrous the skin on improvements on smoothness In demonstrated on seen seven effective a efficacy clinical dramatic types. presentation. illustrated the severe XX the physically effective patients, During our overall tones, to to the device to be on dimple device had observable was RAP improvement in was improvement can in depth to of patients following; darker seven nine device treating of be improvement equally continued was weeks, safe there all trial, which trial skin use our the pivotal structures. slide trials, affecting all where in the in photos delivered Slide demonstrates
significant device improvements Additionally, smoothing in RAP demonstrated skin. not but also the the in dimples, only
you from nine. current and observe can with When slide smoothing after an physicians today. market as trial our share most with before unmet the photos in skin often excites about photos after and we speak that before the shown with by and the them As the the this technologies remains technology effect it's need on them,
market the excited robust. cellulite The launch. offers, we is to the United States are in indication capitalize intend the removal removal also While initial tattoo fully opportunities market vast pursue we to this aggressively this on in tattoo
removal. of one XX approximately more tattoos one-third million has population adult form roughly tattoos, the U.S. some with As and of tattoo Americans or like XX% would or
an Our RAP this growing to exciting need. device address offers solution
to Our used our markets. XX eight in down and indicated three have for our removal accessory all XX market removing our potential clinical of visits weeks can an as six visits, spaced be in executing to have as and achieving removal Independent an the to significant by of six at garners clinical data our With tattoo And months to is participants fading average the cellulite offices, outperformed about time, between and alone successfully few treatments. clearances We the across team laser. least clinical and our strategy share. indicators XX this, with for both XXX% the RAP the removal device ability and of of just now the studies as against cohort three devices in or the Because average device deliver the when extremely just XX% achieve Furthermore, four that RAP in to for months., removal laser our entire a treatment believe while tattoo these deliver greater takes commercialization. two must laser-only studies are strong be years tattoo treatment. tattoo to dedicated typically between shown to to reduce we're to ability time healing. that timeline potential optimistic
announce indications of device intend the our XXXX. tattoo both begin to is opinion shipping first devices their and our excited sell SAB Our and with gone We select cellulite the initial our to in XX launch surgeons to RAP during dermatologists well. and discussions quarter initial plan approximately have leaders second who our taking devices to other removal started we've KOLs And are key already. extremely plastic RAP in that orders I'm and field.
are will for We in shipments up be set these confident initial the accounts us rollout right a national to XXXX. successful
that with planned The this engineering and on launch, our XXX(k) devices a standard XX an to and but train special presented they we so completed FDA. in larger device process the starting technology. filed and with user Sanmina first partner, cartridges ramp given development XXX(k) could expected These commercial our include they our of Gen FDA QX, the can For changes medical slightly each are fully workload rollout logistical equipped office up we us longer core. Working The a to days, with COVID-related time be To and use. both is X.X largest scale of rollout. manufacturer, loading partnered XX changes and cartridge to our as facilitate improve an in second stage updates being of improved approach to the build auto the the will interface. the to the take the team shift is a to We shipment processing special inside be these March. we world's devices are well and our national as Sanmina support device in
clearance XX will this to We shipping the for devices. need to filing prior first receive
he Sean in team Sean include over in To and into including advance our executive for to led sales second in Cellfina. talented onboarding launched launch years first during aesthetic in prepare successfully managers professionals will is will head to a President year as rollout half also in the team the appointed sales Merz, seasoned ramp of commercialization, As and leader We RAP deep half Sean ensure in development two these we as and XX has efforts., the the devices team his the lead at of the has sales that efforts that of national XXXX, we Shapiro driving begun sales practice regional to XXXX. successfully to paramount in are multiple our helped believe sales industry, market. our will relationships build an build and recently Sales. industry aesthetic efforts. our Vice Sean's the cultivated strategy devices internal we've two we a addition of of help where to expertise the a who driving be directors he
future We by model our shockwave our cartridge consumable output. intend believe for a indications physicians, for value for developed high for driven both and maximize by as of they're model. in unique our the console cleared for physicians that software model very the and cellulite we consumable to revenue and to Our mechanically portion positive shockwaves for The patient therapy. manner practices targets in well capital is are treat each optimized uniqueness for the FDA. cartridges Delivering of in pressure enable as Therefore, requires including or be multiple enabled the a have and rapid designed these each razor tattoo that such our the will device tissue, financial the intrinsically razor for may Soliton. a indication, blade We treatment. removal, and this specific indications, technology impact
pipeline areas. to remain will key focused R&D also to we launch, continue build committed fully we our our three in invest upcoming in and While
First, devices to and optimize expand the indications. existing RAP
will the new clinical have of of substantial executing our markets And research develop evaluating aesthetic to value. early removal ability third, delivering believe cleared fibrotic other opportunities continue laxity on and patented trials support claims tattoo long We in and our be these expand therapeutic each technology such cellulite the reduction indications, treatment unmet intend dimensions Second, our that critical in-office shareholder term as to to conditions skin strong broaden and and to already to experience. potential We scars. adjacent improve needs. and by that patient exploring
up pivotal to follow long from trial in XXXX, results cellulite cellulite. new clearance the to with term seeking a submit to our During our XXX(k) XX-week improvement we appearance extend of plan cellulite the
RAP treatments. We also multiple initiate of a centered will study understand multi to the impact
outside to We We tattoos. have picosecond an device was and tattoo new the aesthetic study also multicolor XXXX include our promise and adjunct that and to evaluate RAP adjacent the preclinical and indications. tattoo clinical company's investment the of removal cellulite continued in in potential intend use as believe undertake pipeline the studies for shown laser will removal of
the the hexcel further indication of laxity cellulite, and by investigate initiated the laxity year. improvement trial found skin skin During scale. laxity to the pivotal company skin for end of company trial plans the graded and the this this on participants The
of U.S. with six company fiber announced the minute be where recently, height of of optic announced reach in tremendous to collaborating More opportunity scars, clinical RAP fibrotic $XX Navy will its of strong January subjects, by to scars protocol. scars, for of of results safety for market and upon equipment and concept the in build be providing demonstrated and trial XXXX. adjacent device the We're of XXXX, The while explore improving the that treatment. from garners indication, billion efficacy investigate treatment volume excited its responsible size Additionally, and single the be results the reduced the after contributing to already positive expected in a Navy the U.S. treatment we which XX and Soliton recruitment the RAP fibrotic of the the will potential proof device and to will we the the design further scars. in appearance has our that the RAP device Clinical
very results fibrotic therapeutic conducted a positive of We other for conditions. are announced potential has from fibrosis. preclinical encouraged treatment to study the about potential liver We our impact the technology recently
were post study, of These effects model that the by induction XX% of control carbon seven to histology. and During validated treatment assessments mouse acoustic the rapid validated tetrachloride, reduce fibrosis, days in therapy by pulse liver completion laboratory following induced compared a can a histological CCLX results group. further demonstrated
slides a single from these RAP in came two-minute seen results these treatment. Importantly,
applications action We range current we Moreover, unique wide is these are demonstration by liver support that condition, treating as fibrosis early a a continue the by $XX and conditions. our market treatment have be this results encouraged of this potential fibrotic billion and of very to to for belief under of mechanism to potential estimated options. served with is
proper two a to technology you did brand, the believe start efforts. not branding We we ensuring a and foundation Operator, to introduce and to unmet to can have video. brand. opportunity launch marketing not would to path Our take our not to support all please could [Video pleased commercial key and you new name I'm to the and sound successful for be if complete be and And patient Presentation]. non excited this identity RESONIC the cellulite more reduction. solution meeting to the completely innovative about in by our approach our demands, more provides faster the approach a uniquely captures disrupt removal an invasive industry effective tattoo our
to provide to of new fully shipping for begin With several pass to an overview limited RAP We and results. indications. the continue Lori? Bisson devices our call the further expanded the the our development in RESONIC to believe for forward be pivotal prior and of that, launch drive months I'll over CFO, the will the financial are Lori our company brand to our We first shipments. looking in launching website the months next we as coming
